ORAGENICS, INC. Proceeds from Issuance or Sale of Equity
ORAGENICS, INC. (OGEN) reported Proceeds from Issuance or Sale of Equity of $2.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-03-16
- ORAGENICS, INC. proceeds from issuance or sale of equity for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ORAGENICS, INC. proceeds from issuance or sale of equity for the quarter ending 2025-09-30 was $0.00.
- ORAGENICS, INC. proceeds from issuance or sale of equity for the quarter ending 2025-06-30 was $0.00.
- ORAGENICS, INC. proceeds from issuance or sale of equity for the quarter ending 2025-03-31 was $2.60M.
- ORAGENICS, INC. proceeds from issuance or sale of equity for fiscal 2025 was $2.60M, a 66.01% decline from fiscal 2024.
- ORAGENICS, INC. proceeds from issuance or sale of equity for fiscal 2024 was $7.65M, a 856.25% increase from fiscal 2023.
- ORAGENICS, INC. proceeds from issuance or sale of equity for fiscal 2023 was $800.00K, a 99.13% decline from fiscal 2022.
- ORAGENICS, INC. proceeds from issuance or sale of equity for fiscal 2022 was $92.00M, a 230.94% increase from fiscal 2021.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month | Proceeds from Issuance or Sale of Equity 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $2.60M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $2.60M 10-Q · filed 2025-11-07 | $5.80M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $2.60M 10-Q · filed 2025-08-08 | $5.80M derived: sum of 3 quarters · filed 2025-08-08 | ||
| 2025-03-31 | $2.60M 10-Q · filed 2025-05-09 | $5.80M derived: sum of 2 quarters · filed 2025-05-09 | |||
| 2024-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $7.65M 10-K · filed 2025-03-14 | |||
| 2024-09-30 | $4.45M 10-Q · filed 2024-11-13 | ||||
| 2023-12-31 | $800.00K 10-K · filed 2024-03-29 | ||||
| 2022-12-31 | $92.00M 10-K · filed 2023-04-17 | ||||
| 2021-12-31 | $27.80M 10-K · filed 2023-04-17 | $12.50M 10-K · filed 2022-03-24 | |||
| 2020-12-31 | $27.80M 10-K/A · filed 2022-07-29 | $11.34M 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$65.00K derived: sum of 2 quarters · filed 2020-11-10 | $11.35M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $11.35M 10-Q · filed 2020-08-14 | |||
| 2019-03-31 | $11.42M 10-Q · filed 2020-05-15 | ||||
| 2018-12-31 | $25.11M 10-K · filed 2019-03-29 | ||||
| 2017-12-31 | $9.68M 10-K · filed 2019-03-29 | ||||
| 2016-12-31 | $4.67M 10-K · filed 2019-03-29 | ||||
| 2013-12-31 | $14.90M 10-K · filed 2019-03-29 | ||||
| 2012-12-31 | $13.00M 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |